Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

H1N1 Is Now Most Dominant Flu Strain Worldwide, WHO Says

November 6, 2009

The H1N1 (swine flu) virus is now the dominant flu strain worldwide, the WHO reported Thursday, with the virus accounting for up to 70 percent of the flu viruses sampled in some countries, the Associated Press reports. "We remain quite concerned about the patterns that we're seeing," Keiji Fukuda, the WHO's special adviser on pandemic influenza to the director-general, said during a press briefing. However, "[Fukuda] said the swine flu virus appeared to be fairly stable, and that samples from around the world remained very similar to when the virus was first identified in April," the news service writes (Cheng, 11/5).

During the press conference, Fukuda spoke of a growing body of evidence from ongoing H1N1 vaccination campaigns in 20 countries that demonstrates the safety and effectiveness of the H1N1 vaccine, the Canadian Press reports. "We now have good evidence, based on many people receiving the vaccines, that we have no picture of unusual side-effects emerging," Fukuda said. "And the side-effects which are expected -- such as a painful injection or perhaps some swelling at the injection site -- these are occurring at rates which are expected and usually seen with seasonal influenza vaccine. So the picture right now looks quite good in terms of the safety," he added (Branswell, 11/5).

"[Fukuda] complained ... that the agency has yet to receive most of the 200 million doses of vaccine that were to be donated by 11 countries," according to the Los Angeles Times' blog, "Booster Shots." "Delays in production of the vaccine have led to shortages, and most countries, like the United States, have chosen to vaccinate their high-priority groups before making good on their pledges" (Maugh, 11/5).

Advertisement
Fukuda "warned the public not to treat the virus like just another flu," pointing to the severe symptoms the virus causes in young people and H1N1's ability to flourish in the summer months, CNN reports. He pointed to regions where H1N1 activity was on the rise, including Europe and Central and Western Asia (11/5).

"We anticipate seeing continued or increased activity during the winter period in the northern hemisphere," Fukuda said, Reuters reports. "This also means that we expect to see continued reports of serious cases and deaths." To date, at least 5,712 people worldwide have died from H1N1, according to the WHO (Nebehay, 11/5).

New York Times Examines Antiviral Peramivir

The New York Times examines the experimental antiviral, peramivir, which is delivered "intravenously, making it usable by hospitalized patients who are too ill to take two approved flu drugs that work against the virus in similar ways -- Tamiflu by Roche, which is typically given as a pill, or Relenza from GlaxoSmithKline, which is inhaled." The U.S. government on Thursday ordered 10,000 "treatment courses of peramivir" to be added to the national stockpile.

Though peramivir has yet to receive FDA approval, it recently "granted authority for the drug to be used in emergencies for patients hospitalized with H1N1 flu who cannot take or do not benefit from Tamiflu or Relenza," the newspaper writes. "Of the 32 patients who received the drug that way, 29 were still alive, BioCryst said in late October," according to the New York Times.

"Although there are still questions about peramivir's true effectiveness, some critics say the government moved too slowly to make the drug available, and that even now, access is too restricted. For each patient, doctors must call an 800 number or fill out a form on a Web site run by the Centers for Disease Control and Prevention. The drug is then sent overnight from a central stockpile," the newspaper writes.

"If you have a critically ill patient, to delay therapy, it's just incomprehensible to me," said Richard Whitley, the president of the Infectious Diseases Society of America, who encouraged the distribution of the drug so that hospitals could have it on hand (Pollack, 11/5).

Back to other news for November 2009


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
Whatever Happened to H1N1 (Swine Flu) and HIV? New Answers at CROI 2010
FAQs About H1N1 Flu From The Body's "Ask the Experts" Forums
Swine Influenza and You
Preventing the Flu: Good Health Habits Can Help Stop Germs
More H1N1 (Swine) Flu International News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement